Share This Link

Increased protein in circulation:Infants actually have lower plasma protein levels (e.g., albumin), reducing protein-binding capacity and increasing the free active drug in circulation.

Fat composition lower than 0.001%:This is incorrect; infants have a lower proportion of body fat than adults, but not nearly as low as 0.001%. Body fat typically makes up around 10–15% in newborns.

More muscular body composition:Infants have less developed muscle mass, which can affect intramuscular drug absorption and distribution, but this is not the primary difference influencing therapeutic dosing.

“This drug causes problems in the human fetus, so you should not take this medication.”This statement would apply to Category X or some Category D drugs, not Category A.

“This drug may cause problems in the human fetus, but nothing has been proven in clinical trials. It is best not to take this medication.”
This describes the uncertainty of Category C drugs, not Category A.

“This drug has not caused problems in animals, but no testing has been done in humans. It is probably safe to take.”This is consistent with Category B, where animal studies show no risk but human data is lacking.

Decreased renal blood flow – Pregnancy increases, not decreases, renal blood flow due to cardiovascular adaptations that enhance perfusion to support maternal and fetal needs.

No change from pre-pregnancy values – Drug excretion changes substantially during pregnancy; assuming no change would ignore the documented increase in GFR.

Complete cessation of drug clearance via kidneys – This never occurs under normal pregnancy physiology; instead, clearance usually increases.

Weeks 1–2 post-conception – This pre-embryonic stage follows fertilization and ends with implantation. Teratogen exposure here usually leads to an all-or-none effect: either the embryo survives with no damage or it results in early pregnancy loss. Major malformations are uncommon at this stage.

Weeks 9–40 post-conception – The fetal period is focused on growth, maturation, and refinement of function. Teratogens here are more likely to cause functional deficits (e.g., cognitive impairment, hearing loss) or mild structural changes, but not major malformations.

The postpartum period – At this point, organogenesis has been completed. Teratogens no longer cause developmental defects, but some drugs can still harm the infant through lactation exposure, potentially causing toxicity or developmental delays.

Deltoid – In neonates, the deltoid muscle is underdeveloped and too small to accommodate most IM doses safely. Using this site increases the risk of poor absorption and nerve injury.

Dorsogluteal – Not recommended for neonates because it poses a significant risk of sciatic nerve injury and has less predictable absorption due to variable fat distribution in infants.

Ventrogluteal – Although a safe site in older children and adults, it is not the first choice in neonates due to limited muscle development in this area during the early months of life.

Mixing drugs into a full bottle of milk – This is not recommended because the child may not finish the bottle, leading to partial dosing and reduced effectiveness of the medication.

Letting the child take medicine unsupervised to build trust – Unsafe for toddlers due to the risk of overdose, spills, and non-compliance. Medication should always be administered under adult supervision.

Crushing tablets without consulting a pharmacist – This may alter drug absorption, destroy protective coatings, or change drug effectiveness. Always confirm with a pharmacist before altering medication form.